Publication: IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases
dc.contributor.author | Thiagarajan, Divya | |
dc.contributor.author | Oparina, Nina | |
dc.contributor.author | Lundström, Susanna | |
dc.contributor.author | Zubarev, Roman | |
dc.contributor.author | Sun, Jitong | |
dc.contributor.author | Alarcon-Riquelme, Marta | |
dc.contributor.author | Frostegård, Johan | |
dc.contributor.authoraffiliation | [Thiagarajan,D; Oparina,N; Sun,J; Alarcon-Riquelme,M; Frostegård,J] Unit of Immunology and Chronic Disease, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. [Lundström,S; Zubarev,R] Division of Physiological Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden. [Alarcon-Riquelme,M] GENYO, Center for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Government, Parque tecnolуgico de la salud, Granada, Spain. | |
dc.contributor.funder | PRECISESADS Clinical Consortium Members: Te research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n°115565, resources of which are composed of fnancial contribution from the European Union’s Seventh Framework Programme (FP7/2007–2013) and EFPIA companies in kind contribution. Swedish Heart Lung foundation and Swedish Rheumatism Association also contributed to fnancing. Open access funding provided by Karolinska Institute. | |
dc.contributor.group | The PRECISESADS Clinical Consortium | es_ES |
dc.date.accessioned | 2022-11-17T09:34:40Z | |
dc.date.available | 2022-11-17T09:34:40Z | |
dc.date.issued | 2020-07-03 | |
dc.description.abstract | IgM antibodies against phosphorylcholine (anti-PC) and malondialdehyde (anti-MDA) may have protective properties in cardiovascular and rheumatic diseases. We here compare these antibodies in systemic rheumatic conditions and study their properties. Anti-PC and anti-MDA was measured using ELISA in patients with SLE (374), RA (354), Mixed connective tissue disease (MCTD, 77), Systemic sclerosis (SSc, 331), Sjögren's syndrome (SjS, 324), primary antiphospholipid syndrome (PAPs, 65), undifferentiated connective tissue disease (UCTD, 118) and 515 matched healthy controls (HC). Cardiovascular score (CV) was broadly defined based on clinical disease symptoms. Anti-PC and anti-MDA peptide/protein characterization were compared using a proteomics de novo sequencing approach. anti-MDA and anti-PC were extracted from total IgM. The proportion of Treg cells was determined by flow cytometry. The maximal difference between cases and controls was shown for MCTD: significantly lower IgM Anti-PC but not anti-MDA among patients (median 49.3RU/ml vs 70.4 in healthy controls, p(t-test) = 0.0037). IgM low levels were more prevalent in MCTD, SLE, SjS, SSc and UCTD. IgM anti-PC variable region profiles were different from and more homologous than anti-MDA. Anti-PC but not anti-MDA were significantly negatively correlated with CV in the whole patient group. In contrast to IgM anti-PC, anti-MDA did not promote polarization of Tregs. Taken together, Anti-PC is decreased in MCTD and also in SLE, SjS and SSc but not in other studied diseases. Anti-PC may thus differentiate between these. In contrast, anti-MDA did not show these differences between diseases studied. Anti-PC level is negatively correlated with CV in the patient group cohort. In contrast to anti-PC, anti-MDA did not promote Treg polarization. These findings could have both diagnostic and therapeutic implications, one possibility being active or passive immunization with PC in some rheumatic conditions. | es_ES |
dc.description.version | Yes | es_ES |
dc.identifier.citation | Thiagarajan D, Oparina N, Lundström S, Zubarev R, Sun J; PRECISESADS Clinical Consortium, et al. IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases. Sci Rep. 2020 Jul 3;10(1):11010 | es_ES |
dc.identifier.doi | 10.1038/s41598-020-66981-z | es_ES |
dc.identifier.essn | 2045-2322 | |
dc.identifier.pmc | PMC7335044 | |
dc.identifier.pmid | 32620913 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10668/4354 | |
dc.journal.title | Scientific Reports | |
dc.language.iso | en | |
dc.page.number | 13 p. | |
dc.publisher | Springer Nature | es_ES |
dc.relation.publisherversion | https://www.nature.com/articles/s41598-020-66981-z | es_ES |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.accessRights | Acceso abierto | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Malondialdehyde | es_ES |
dc.subject | Phosphorylcholine | es_ES |
dc.subject | Proteomics | es_ES |
dc.subject | Rheumatic diseases | es_ES |
dc.subject | IgM | es_ES |
dc.subject | Immunoglobulin M | es_ES |
dc.subject | Malondialdehído | es_ES |
dc.subject | Fosforilcolina | es_ES |
dc.subject | Proteómica | es_ES |
dc.subject | Enfermedades reumáticas | es_ES |
dc.subject | Inmunoglobulina M | es_ES |
dc.subject.mesh | Medical Subject Headings::Persons::Persons::Age Groups::Adult | es_ES |
dc.subject.mesh | Medical Subject Headings::Persons::Persons::Age Groups::Adult::Aged | es_ES |
dc.subject.mesh | Medical Subject Headings::Persons::Persons::Age Groups::Adult::Aged::Aged, 80 and over | es_ES |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Antibodies::Autoantibodies | es_ES |
dc.subject.mesh | Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies | es_ES |
dc.subject.mesh | Medical Subject Headings::Check Tags::Female | es_ES |
dc.subject.mesh | Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans | es_ES |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Antibodies::Immunoglobulin Isotypes::Immunoglobulin M | es_ES |
dc.subject.mesh | Medical Subject Headings::Check Tags::Male | es_ES |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Aldehydes::Malondialdehyde | es_ES |
dc.subject.mesh | Medical Subject Headings::Persons::Persons::Age Groups::Adult::Middle Aged | es_ES |
dc.subject.mesh | Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Amines::Quaternary Ammonium Compounds::Trimethyl Ammonium Compounds::Choline::Phosphorylcholine | es_ES |
dc.subject.mesh | Medical Subject Headings::Disciplines and Occupations::Natural Science Disciplines::Biological Science Disciplines::Biochemistry::Proteomics | es_ES |
dc.subject.mesh | Medical Subject Headings::Diseases::Musculoskeletal Diseases::Rheumatic Diseases | es_ES |
dc.subject.mesh | Medical Subject Headings::Persons::Persons::Age Groups::Adult::Young Adult | es_ES |
dc.title | IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases | es_ES |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 2 of 2
Loading...
- Name:
- Thiagarajan_IgMAntibodies.pdf
- Size:
- 1.77 MB
- Format:
- Adobe Portable Document Format
- Description:
- Artículo original
Loading...
- Name:
- Thiagarajan_IgMAntibodies_MaterialSuplementario.pdf
- Size:
- 418.66 KB
- Format:
- Adobe Portable Document Format
- Description:
- Material suplementario